India, Oct. 9 -- Global pharma major Lupin Limited has announced the launch of a strategic partnership program to expand the reach of its proprietary long-acting injectable (LAI) platform, PrecisionSphere™, developed by its subsidiary Nanomi B.V.
The program aims to foster collaborations with pharmaceutical companies seeking to extend product lifecycles or develop longer-acting formulations. The announcement follows the U.S. FDA's recent approval of the first product developed using PrecisionSphere™, validating the platform's commercial readiness, safety, and efficacy in drug delivery.
Dr. Fabrice Egros, President – Corporate Development at Lupin, said, "With PrecisionSphere™ now validated, we are ready to expand p...